The Company obtains a financial contribution from the CNRC-IRAP
program for the development of a White Blood Cell Automated Image
Shares Outstanding: 20,749,810
LONGUEUIL, QC,June 29 /CNW Telbec/ - Clemex Technologies Inc. (TSX
Venture: CXG.a) announces today that the Company is creating a new division
which has the mission of developing medical instruments based on its expertise
in quantitative microscopy systems. Clemex will design, develop and bring to
market medical instruments, for hematology and pathology applications.
In addition to offering technical expertise, the Canadian National
Research Council (CNRC), through its IRAP program, will participate to the
$815,000 research project in the form a grant of up to $482,000. This
investment will be committed a research project for the development of a
microscopy blood cells analyzer. The project, which began June 1 2009, will
end in 15 months with the delivery of the first units. This new instrument
will play a complementary role to the traditional chemical analysis
instruments at it will allow for automated image analysis of the 20% of blood
samples that cannot be processed chemically and that are currently analyzed by
optical microscopy. While these samples are currently examined visually by
qualified personnel with all the associated inconvenience, the new Clemex
instrument will more than double the precision of the results, since it will
classify two to three times more white blood cells than a microscopist and
this in a few minutes. Furthermore, it will be possible to analyze two or
three slides per patient rather than one, making the results even more
During the same period of time, Clemex's French business partner,
Réactifs RAL of Bordeaux, France, will be developing chemical reagents
specifically design for automated microscopy systems such as the instrument
conceived and fabricated by Clemex.
A team of eight people will be dedicated to the design and conception of
the instrument, while external consultants will be coaching Clemex for
compliancy with Health Canada and FDA Rules and Regulations prior to
commercialization. An Hematologist from the Montreal Jewish Hospital, Dr.
Martin Gyger, will be consulted by the R&D team on a continuous basis for his
Following the launch of the project, Dr. Gyger declared: "I am deeply
honored and enthusiastic to be involved in the development of such an
instrument to assist in the diagnosis of blood pathologies. With the short
supply of qualified medical personnel, combined with aging population and
continuously increasing costs of Health Services, there is no doubt in my mind
that there is a need for such medical instruments." He carried on by adding:
"I have been meeting with the Clemex R&D team on a regular basis over the last
few months to prepare this project, and I am convinced that Clemex already
possess a substantial part of the required technology and that they have the
expertise to conceive and build a first class instrument."
Clement Forget, President and CEO of CLEMEX added: "With the current
economic slowdown in the manufacturing industry, which is likely to continue
for a while, we had to explore other, more promising markets in order to
sustain our growth and the medical instrument and health market is one of
first choice. The hematology application alone represents a market of 2
billion $, with a minimum potential of 2,500 instruments in North America and
He carried on: "Furthermore, the recent exposure of possible inadequate
breast cancer diagnosis related to pathological blood slides analysis,
demonstrates that there will be an increasing need for powerful and reliable
medical instruments which offer reproducible results, at the fraction of the
cost of qualified personnel. This long awaited instrument will be the perfect
complement for numerous hematology testing laboratories."
About Clemex Technologies, Inc.
Clemex Technologies Inc. develops, manufactures and markets image
analysis systems and software used by medical, quality control and research
microscopy laboratories. Clemex's customer base spans over many countries in
America, Europe, Asia and encompasses major Research and Development Centers,
Hospitals, prestigious Universities and large manufacturing industries in
various fields including health science, automotive, aerospace, raw materials
manufacturing, pharmaceuticals, mining and other sectors.
The CDNX has not reviewed and does not accept responsibility for the
adequacy and accuracy of this news release.
For further information:
For further information: Clément Forget, Clemex Technologies Inc, (450)